You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: RE45105

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: RE45105

Title:	Method of treating cancer by co-administration of anticancer agents
Abstract:	The present invention relates to a method of treating cancer by co-administration of an effective amount of 1-(2-methoxy-ethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro- -1H-naphtho[2,3-d]imidazol-3-ium bromide and an effective amount of one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, docetaxel, doxorubicin, dacarbazine and rituximab, or a retuximab-containing combination therapy selected from R-ICE and R-DHAP. The treatment method of the present invention is useful for the treatment for all solid tumors and lymphomas, preferably skin cancer, bladder cancer, breast cancer, uterine cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer and the like. Particularly, they are expected as therapeutic agents for tumor types which show resistance against existing anticancer agents.
Inventor(s):	Nakahara; Takahito (Chuo-ku, JP), Yamanaka; Kentaro (Chuo-ku, JP), Kita; Aya (Chuo-ku, JP), Koutoku; Hiroshi (Chuo-ku, JP)
Assignee:	Astellas Pharma Inc. (Tokyo, JP)
Application Number:	13/973,071
Patent Claims:	1. A method for treatment of a cancer patient .Iadd.with lymphoma.Iaddend., which comprises administering an effective amount of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-- 1H-naphtho[2,3-d]imidazol-3-ium bromide to said patient, combined with .[.i).]. .Iadd.an effective amount of .Iaddend.rituximab.[., ii) a combination therapy R-ICE consisting of rituximab, ifosfamide, carboplatin and etoposide, or iii) a combination therapy R-DHAP consisting of rituximab, cytarabine and cisplatin as anticancer agents.].. .[.2. The method as claimed in claim 1, wherein rituximab is combined with said effective amount of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-- 1H-naphtho[2,3-d]imidazol-3-ium bromide..]. 3. The method as claimed in claim 1, wherein .Iadd.said rituximab is administered as a member of .Iaddend.a combination therapy .[.selected from the group consisting of R-ICE and.]. R-DHAP .[.is combined with said effective amount of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-- 1H-naphtho[2,3-d]imidazol-3-ium bromide.].. 4. The method as claimed in claim .[.3.]. .Iadd.1.Iaddend., wherein .Iadd.said rituximab is administered as a member of a combination therapy .Iaddend.R-ICE .[.is combined with said effective amount of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-- 1H-naphtho[2,3-d]imidazol-3-ium bromide.].. .[.5. The method as claimed in claim 1, wherein the patient has lymphoma..]. 6. The method as claimed in claim 1, wherein said 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-- 1H-naphtho[2,3-d]imidazol-3-ium bromide is administered intravenously by infusion at a dose of 1-10 mg/m.sup.2/day continuously for a period of 4-14 days. 7. A method as claimed in claim 6, wherein said 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-- 1H-naphtho[2,3-]imidazol-3-ium bromide is administered intravenously by infusion at a dose of 3-8 mg/m.sup.2/day continuously for 7 days followed by 14 days of no 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-- 1H-naphtho[2,3-d]imidazol-3-ium bromide, after which the entire administration cycle can be repeated depending on the patient's conditions. .[.8. A kit comprising at least one cycle dosage of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-- 1H-naphtho[2,3-d]imidazol-3-ium bromide and i) rituximab, ii) anticancer agents for a combination therapy R-ICE consisting of rituximab, ifosfamide, carboplatin and etoposide, or iii) anticancer agents for a combination therapy R-DHAP consisting of rituximab, cytarabine and cisplatin as anticancer agents..].

Details for Patent RE45105

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997	⤷ Try a Trial	2026-12-29
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002	⤷ Try a Trial	2026-12-29
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017	⤷ Try a Trial	2026-12-29
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.